GRAFTON – Haley was a little nervous during her doctor's appointment. She shivered and cowered, but her mood quickly improved. Haley had a leg amputated nearly a year ago after a diagnosis of an ...

From the election of Zohran Mamdani to the intrigue surrounding the jewel heist at the Louvre, keeping up with this year's news also left some Americans struggling with pronunciations. That's put both ...

Osteosarcoma primarily affects long bones in teenagers and young adults, requiring early diagnosis for effective treatment. Treatment strategies vary by stage, with surgery and chemotherapy as primary ...

Please provide your email address to receive an email when new articles are posted on . Inherited mutations in SMARCAL1 are significantly linked to osteosarcoma risk, an analysis of DNA damage repair ...

Languages are challenging for many reasons, from strange nickname origins to confusing text abbreviations. Pronunciation is yet another thing that makes languages more challenging to learn. That said, ...

The United States is a rich tapestry of cultures, languages , and history, and this diversity is reflected in the names of its 50 states. While many may look simple at first glance, many state names ...

Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

A new review was published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” Authors ...

A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced ...

Researchers published a new study, “Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution,” in Cell that they say solves the mystery of what drives the genomic ...

GSK’227, a B7-H3-targeted ADC, received FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma after two prior therapies. Phase 2 ARTEMIS-002 study showed antitumor activity and ...